Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S274100
Reexamination Certificate
active
10130018
ABSTRACT:
The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.
REFERENCES:
patent: 3707475 (1972-12-01), Lombardino
patent: 3940486 (1976-02-01), Fitzi
patent: 4348404 (1982-09-01), Whitney
patent: 4447431 (1984-05-01), Sallmann
patent: 5166214 (1992-11-01), Billheimer et al.
patent: 5179117 (1993-01-01), Maduskuie, Jr.
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5310748 (1994-05-01), Wilde et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 5552557 (1996-09-01), Fujii et al.
patent: 5620999 (1997-04-01), Weier et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5717100 (1998-02-01), Selnick et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 6040320 (2000-03-01), Beers et al.
patent: 6207687 (2001-03-01), Claiborne et al.
patent: 6235760 (2001-05-01), Feuerstein
patent: 6342510 (2002-01-01), Isakson et al.
patent: 6436966 (2002-08-01), Ohkawa et al.
patent: 6548520 (2003-04-01), Adams et al.
patent: 6602877 (2003-08-01), Banborough et al.
patent: 2003/0134837 (2003-07-01), Gaiba et al.
patent: 2003/0153588 (2003-08-01), Steadman et al.
patent: 2004/0038964 (2004-02-01), Dean et al.
patent: 2004/0053943 (2004-03-01), Adams et al.
patent: 2004/0127496 (2004-07-01), Dean et al.
patent: 2004/0192689 (2004-09-01), Dean et al.
patent: 2004/0198730 (2004-10-01), Dean et al.
patent: 2004/0209883 (2004-10-01), Bamford et al.
patent: 2004/0235843 (2004-11-01), Bamford et al.
patent: 2004/0248896 (2004-12-01), Dean et al.
patent: 2004/0254186 (2004-12-01), Dean et al.
patent: WO 97/36587 (1997-10-01), None
patent: WO 98/16227 (1998-04-01), None
patent: WO 99/01449 (1999-01-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 99/061437 (1999-12-01), None
patent: WO 00/01688 (2000-01-01), None
patent: WO 00/26209 (2000-05-01), None
patent: WO 00/33836 (2000-06-01), None
patent: WO 00/64422 (2000-11-01), None
patent: WO 01/37835 (2001-05-01), None
patent: WO 01/38324 (2001-05-01), None
CA 130:95507, Claiborne et al. 1998.
CA 135:19656, Dean et al.2001.
Revesz, “Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles and their preparation, compositions, and use”, Abstract WO 2000026209, May 11, 2000, AN 2000:314693.
“Preparation of pyridinylimidazoles for treatment of DSBP kinase mediated disease”, Abstract WO 9961437, Dec. 2, 1999, AN 1999:764034.
Adams et al.,Bioorganic&Medical Chemistry Letters, vol. 8 pp. 3111-3116 (1998).
Adams et al.,Current Opinion in Drug Discovery and Development, vol. 2(2) pp. 96-109 (1999).
Antolini et al.,Bioorganic&Medical Chemistry Letters, vol. 9 pp. 1023-1028 (1999).
Astles et al.,J. Med. Chem.,vol. 39 pp. 1423-1432 (1996).
Bilodeau et al.,J. Org. Chem.,vol. 63 pp. 2800-2801 (1998).
Boehm et al.,Exp Opinion Ther. Patents, vol. 10(1) pp. 25-37 (2000).
Boehm et al.,J. Med Chem.,vol. 39 pp. 3929-3937 (1996).
Claiborne et al.,Tetrahedron Letters, vol. 39 pp. 8939-8942 (1998).
Cuenda et al.,FEBS Letters, vol. 364 pp. 229-233 (1995).
de Laszlo et al.,Bioorganic&Medical Chemistry Letters, vol. 8 pp. 2689-2694 (1998).
Dumas et al.,Bioorganic&Medical Chemistry Letters, vol. 10 pp. 2047-2050 (2000).
Dumas et al.,Bioorganic&Medical Chemistry Letters,vol. 10 2051-2054 (2000).
Eberwein et al.,Clinical Cancer Researc, vol. 6 (Supple.) Poster session 17 p. 4547(406) (Nov. 2000).
Engel et al.,Liebigs Ann. Chem.,p. 1916-1927 (1978).
Fischer et al.,Rec.Trav.Chim.Pays.Bas.,vol. 84 p. 439-440 (1965).
Gallagher et al.,Bioorganic&Medical Chemistry, vol. 5(1) pp. 49-64 (1997).
Garcia-Echeverria et al.,Med. Res. Reviews, vol. 20(1) pp. 28-57 (2000).
Garigipati, R.,Tetrahedron Letters, vol. 31(14) pp. 1969-1972 (1990).
Hall-Jackson et al.,Oncogene, vol. 18 pp. 2047-2054 (1999).
Heimbrock et al., “Identification of Potent, Selective Inhibitors of Raf Protein Kinase,”Amer. Assoc for Cancer Res New OrleansAbstract 3793 Apr. 1998.
Henry et al.,Bioorganic&Medical Chemistry Letters, vol. 8 pp. 3335-3340 (1998).
Henry et al.,Drugs of the Future, vol. 24(12) pp. 1345-1354 (1999).
Ishibashi,Chem. Pharm. Bull.,vol. 37(8), pp. 2214-2216 (1989).
Johnson,J. Chem.Soc.,Perkin Trans., vol. 1, pp. 895-905 (1996).
Katritzky,Synthesis, pp. 45-47 (1993).
Minato et al.,Tetrahedron Letters, vol. 22, p. 5319-5322 (1981).
Lackey et al.,Bioorganic&Medical Chemistry Letters, vol. 10 pp. 223-226 (2000).
Lee et al.,Pharmacol Ther., vol. 82(2-3) pp. 389-397 (1999).
Lisnock et al.,BioChemistry, vol. 37 pp. 16573-16581 (1998).
Liverton et al.,J. Med Chem.,vol. 42 pp. 2180-2190 (1999).
Lowinger et al., Clinical Cancer Research, vol. 6(No. 335) (Suppl.) Poster session 13 p. 4533 (Nov. 2000).
Morton et al.,Tetrahedron Letters, 4123-4124 (1982).
Pridgen,J. Org.Chem.,vol. 47, p. 4319-4323 (1982).
R.P.Soni,Aust.J.Chem.,vol. 35, p. 1493-6 (1982).
Revesz et al.,Bioorganic&Medical Chemistry Letters, vol. 10 pp. 1261-1264 (2000).
Salituro et al.,Current Medicinal Chemistry, vol. 6 pp. 807-823 (1999).
Alves, et al.,Tetrahedron Letters, vol. 29, pp. 2135-2136 (1988).
Echavarres et al.,J.Amer.Chem.Soc.,vol. 109, pp. 5478-5486 (1978).
Stover et al.,Current Opinion in Drug Discovery and Development, vol. 2(4) pp. 274-285 (1999).
Strzybny et al.,J. Org. Chem.,vol. 28, pp. 3381-3383 (1963).
Ishikura et al., M.,Chem.Pharm.Bull.,vol. 11, pp. 4755-4757 (1985).
Thompson, et al.,J.Org.Chem.,vol. 49, pp. 5237-5243 (1984).
Toledo et al.,Current Medicinal Chemistry, vol. 6 pp. 775-805 (1999).
Tong et al.,Nature Structural Biology, vol. 4(4) pp. 311-316 (1997).
Ashley Publications, “Two Novel structural classes of p38 Kinase inhibitors,”Exp Opin. Ther. Patentsvol. 9(4) pp. 477-480 (1999).
Uno, Bull.Chem. Soc. Japan.,vol. 69, pp. 1763-1767 (1996).
VanLeusen et al.,J.O.C.,vol. 42 (7) pp. 1153-1159 (1977).
Ashley Publications, “p38 Inhibitors based on the pyridylurea and pyridylacetoamide templates,”Exp Opin. Ther. Patents, vol. 10(7) pp. 1151-1154 (2000).
Wang et al.,Structure, vol. 6(9) pp. 1117-1128 (Sep. 15, 1998).
Young et al.,The Journal of Biological Chemistry, vol. 272(18) pp. 12116-12121 (1997).
Zavyalov, et al.,Khim Farm Zh, vol. 26(3), p. 88 (1992) (With Translation).
Adams Jerry L.
Johnson Neil W.
Murray Jeffrey H.
Dinner Dara L.
Kinzig Charles M.
Morris Patricia L.
SmithKline Beecham Corporation
Venetianer Stephen
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736427